

- cell line," *Journal of Urology*, vol. 159, no. 2, pp. 586–590, 1998.
- [75] M. Stoker, E. Gherardi, M. Perryman, and J. Gray, "Scatter factor is a fibroblast-derived modulator of epithelial cell mobility," *Nature*, vol. 327, no. 6119, pp. 239–242, 1987.
- [76] D. P. Bottaro, J. S. Rubin, D. L. Faletto et al., "Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product," *Science*, vol. 251, no. 4995, pp. 802–804, 1991.
- [77] E. M. Rosen, A. Joseph, L. Jin et al., "Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder," *Journal of Urology*, vol. 157, no. 1, pp. 72–78, 1997.
- [78] T. Tamatani, K. Hattori, A. Iyer, K. Tamatani, and R. Oyasu, "Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro," *Carcinogenesis*, vol. 20, no. 6, pp. 957–962, 1999.
- [79] D. M. Ornitz and N. Itoh, "Fibroblast growth factors," *Genome Biology*, vol. 2, no. 3, article 3005, 2001.
- [80] P. Gazzaniga, O. Gandini, A. Gradilone et al., "Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses," *International Journal of Oncology*, vol. 14, no. 6, pp. 1123–1127, 1999.
- [81] D. K. Chopin, J. P. Caruelle, M. Colombel et al., "Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine," *Journal of Urology*, vol. 150, no. 4, pp. 1126–1130, 1993.
- [82] J. Jouanneau, J. Gavrilovic, D. Caruelle et al., "Secreted or nonsecreted forms of acidic fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility, and invasive potential," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 88, no. 7, pp. 2893–2897, 1991.
- [83] H. Miyake, K. Yoshimura, I. Hara, H. Eto, S. Arakawa, and S. Kamidono, "Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines," *Journal of Urology*, vol. 157, no. 6, pp. 2351–2355, 1997.
- [84] L. Cheng, S. Zhang, G. T. MacLennan, S. R. Williamson, A. Lopez-Beltran, and R. Montironi, "Bladder cancer: translating molecular genetic insights into clinical practice," *Human Pathology*, vol. 42, no. 4, pp. 455–481, 2010.
- [85] F. M. Watt, "Role of integrins in regulating epidermal adhesion, growth and differentiation," *EMBO Journal*, vol. 21, no. 15, pp. 3919–3926, 2002.
- [86] M. Liebert, R. Washington, J. Stein, G. Wedemeyer, and H. B. Grossman, "Expression of the VLA β 1 integrin family in bladder cancer," *American Journal of Pathology*, vol. 144, no. 5, pp. 1016–1022, 1994.
- [87] H. B. Grossman, C. Lee, J. Bromberg, and M. Liebert, "Expression of the α 6 β 4 integrin provides prognostic information in bladder cancer," *Oncology Reports*, vol. 7, no. 1, pp. 13–16, 2000.
- [88] J. S. Sebolt-Leopold, "Development of anticancer drugs targeting the MAP kinase pathway," *Oncogene*, vol. 19, no. 56, pp. 6594–6599, 2000.
- [89] M. Hatakeyama and R. A. Weinberg, "The role of RB in cell cycle control," *Progress in Cell Cycle Research*, vol. 1, pp. 9–19, 1995.
- [90] P. Korkolopoulou, P. Christodoulou, A. E. Konstantinidou, E. Thomas-Tsagli, P. Kapralos, and P. Davaris, "Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1," *Human Pathology*, vol. 31, no. 6, pp. 751–760, 2000.
- [91] W. R. Taylor and G. R. Stark, "Regulation of the G2/M transition by p53," *Oncogene*, vol. 20, no. 15, pp. 1803–1815, 2001.
- [92] Y. Kubota, H. Miyamoto, S. Noguchi et al., "The loss of retinoblastoma gene in association with c-myc and transforming growth factor- β 1 gene expression in human bladder cancer," *Journal of Urology*, vol. 154, no. 2, part 1, pp. 371–374, 1995.
- [93] C. Cordon-Cardo, D. Wartinger, D. Petrylak et al., "Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer," *Journal of the National Cancer Institute*, vol. 84, no. 16, pp. 1251–1256, 1992.
- [94] R. J. Cote, M. D. Dunn, S. J. Chatterjee et al., "Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53," *Cancer Research*, vol. 58, no. 6, pp. 1090–1094, 1998.
- [95] I. Orlow, H. LaRue, I. Osman et al., "Deletions of the INK4A gene in superficial bladder tumors: association with recurrence," *American Journal of Pathology*, vol. 155, no. 1, pp. 105–113, 1999.
- [96] T. W. McGarvey, E. Tait, J. E. Tomaszewski, and S. B. Malkowicz, "Expression of transforming growth factor- β receptors and related cell-cycle components in transitional-cell carcinoma of the bladder," *Molecular Urology*, vol. 3, no. 4, pp. 371–379, 1999.
- [97] S. Sarkar, K. P. Jülicher, M. S. Burger et al., "Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers," *Cancer Research*, vol. 60, no. 14, pp. 3862–3871, 2000.
- [98] H. Miyamoto, Y. Kubota, T. Shuin, S. Torigoe, Y. Dobashi, and M. Hosaka, "Expression of transforming growth factor-beta 1 in human bladder cancer," *Cancer*, vol. 75, no. 10, pp. 2565–2570, 1995.
- [99] L. M. Coombs, D. A. Pigott, M. E. Eydmann, A. J. Proctor, and M. A. Knowles, "Reduced expression of TGF β is associated with advanced disease in transitional cell carcinoma," *British Journal of Cancer*, vol. 67, no. 3, pp. 578–584, 1993.
- [100] J. D. Kelly, K. E. Williamson, A. E. Irvine et al., "Apoptosis and its clinical significance for bladder cancer therapy," *BJU International*, vol. 83, no. 1, pp. 1–10, 1999.
- [101] A. Morrione, B. Valentini, S. Q. Xu et al., "Insulin-like growth factor II stimulates cell proliferation through the insulin receptor," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 8, pp. 3777–3782, 1997.
- [102] A. J. Butt, S. M. Firth, and R. C. Baxter, "The IGF axis and programmed cell death," *Immunology and Cell Biology*, vol. 77, no. 3, pp. 256–262, 1999.
- [103] A. Ashkenazi and V. M. Dixit, "Apoptosis control by death and decoy receptors," *Current Opinion in Cell Biology*, vol. 11, no. 2, pp. 255–260, 1999.
- [104] D. R. Green and J. C. Reed, "Mitochondria and apoptosis," *Science*, vol. 281, no. 5381, pp. 1309–1312, 1998.
- [105] D. Ye, H. Li, S. Qian, Y. Sun, J. Zheng, and Y. Ma, "bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection," *Journal of Urology*, vol. 160, no. 6, part 1, pp. 2025–2029, 1998.
- [106] I. Giannopoulou, L. Nakopoulou, A. Zervas et al., "Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: Prognostic implications," *Urological Research*, vol. 30, no. 5, pp. 342–345, 2002.

- [107] S. A. Hussain, R. Ganesan, L. Hiller et al., "Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder," *British Journal of Cancer*, vol. 88, no. 4, pp. 586–592, 2003.
- [108] S. A. Hussain, R. Ganesan, L. Hiller et al., "BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder," *Oncology Reports*, vol. 10, no. 3, pp. 571–576, 2003.
- [109] P. W. Cooke, N. D. James, R. Ganesan, A. Burton, L. S. Young, and D. M. A. Wallace, "Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy," *BJU International*, vol. 85, no. 7, pp. 829–835, 2000.
- [110] Y. Mizutanil, O. Yoshida, and B. Bonavida, "Prognostic significance of soluble Fas in the serum of patients with bladder cancer," *Journal of Urology*, vol. 160, no. 2, pp. 571–576, 1998.
- [111] U. Bugajska, N. T. Georgopoulos, J. Southgate et al., "The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis," *Journal of the National Cancer Institute*, vol. 94, no. 18, pp. 1381–1395, 2002.
- [112] P. W. Cooke, N. D. James, R. Ganesan, M. Wallace, A. Burton, and L. S. Young, "CD40 expression in bladder cancer," *Journal of Pathology*, vol. 188, no. 1, pp. 38–43, 1999.
- [113] C. M. Counter, A. A. Avilion, C. E. Lefevre et al., "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity," *EMBO Journal*, vol. 11, no. 5, pp. 1921–1929, 1992.
- [114] K. Yoshida, T. Sugino, H. Tahara et al., "Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine," *Cancer*, vol. 79, no. 2, pp. 362–369, 1997.
- [115] M. Müller, "Telomerase: its clinical relevance in the diagnosis of bladder cancer," *Oncogene*, vol. 21, no. 4, pp. 650–655, 2002.
- [116] T. Veikkola and K. Alitalo, "VEGFs, receptors and angiogenesis," *Seminars in Cancer Biology*, vol. 9, no. 3, pp. 211–220, 1999.
- [117] K. M. Dameron, O. V. Volpert, M. A. Tainsky, and N. Bouck, "Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1," *Science*, vol. 265, no. 5178, pp. 1582–1584, 1994.
- [118] E. H. Streeter and A. L. Harris, "Angiogenesis in bladder cancer—prognostic marker and target for future therapy," *Surgical Oncology*, vol. 11, no. 1–2, pp. 85–100, 2002.
- [119] B. H. Bochner, R. J. Cote, N. Weidner et al., "Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis," *Journal of the National Cancer Institute*, vol. 87, no. 21, pp. 1603–1612, 1995.
- [120] T. M. Jaeger, N. Weidner, K. Chew et al., "Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer," *Journal of Urology*, vol. 154, no. 1, pp. 69–71, 1995.
- [121] J. P. Crew, T. O'Brien, M. Bradburn et al., "Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer," *Cancer Research*, vol. 57, no. 23, pp. 5281–5285, 1997.
- [122] S. Bernardini, S. Fauconnet, E. Chabannes, P. C. Henry, G. Adessi, and H. Bittard, "Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer," *Journal of Urology*, vol. 166, no. 4, pp. 1275–1279, 2001.
- [123] S. C. Campbell, O. V. Volpert, M. Ivanovich, and N. P. Bouck, "Molecular mediators of angiogenesis in bladder cancer," *Cancer Research*, vol. 58, no. 6, pp. 1298–1304, 1998.
- [124] K. J. Turner, J. P. Crew, C. C. Wykoff et al., "The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer," *British Journal of Cancer*, vol. 86, no. 8, pp. 1276–1282, 2002.
- [125] T. Klatte, A. S. Belldegrun, and A. J. Pantuck, "The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder," *BJU International*, vol. 101, supplement 4, pp. 45–48, 2008.
- [126] K. Inoue, J. W. Slaton, D. W. Davis et al., "Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel," *Clinical Cancer Research*, vol. 6, no. 7, pp. 2635–2643, 2000.
- [127] M. Takeichi, "Cadherin cell adhesion receptors as a morphogenetic regulator," *Science*, vol. 251, no. 5000, pp. 1451–1455, 1991.
- [128] L. Shapiro, A. M. Fannon, P. D. Kwong et al., "Structural basis of cell-cell adhesion by cadherins," *Nature*, vol. 374, no. 6520, pp. 327–336, 1995.
- [129] R. A. Foty and M. S. Steinberg, "Measurement of tumor cell cohesion and suppression of invasion by E- or P-cadherin," *Cancer Research*, vol. 57, no. 22, pp. 5033–5036, 1997.
- [130] M. T. Nieman, R. S. Prudoff, K. R. Johnson, and M. J. Wheelock, "N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression," *Journal of Cell Biology*, vol. 147, no. 3, pp. 631–643, 1999.
- [131] J. A. Jankowski, R. Bruton, N. Shepherd, and D. S. A. Sanders, "Cadherin and catenin biology represent a global mechanism for epithelial cancer progression," *Journal of Clinical Pathology—Molecular Pathology*, vol. 50, no. 6, pp. 289–290, 1997.
- [132] P. P. Bringuier, R. Umbas, H. E. Schaafsma, H. F. M. Karthaus, F. M. J. Debruyne, and J. A. Schalken, "Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors," *Cancer Research*, vol. 53, no. 14, pp. 3241–3245, 1993.
- [133] L. A. Ribeiro-Filho, J. Franks, M. Sasaki et al., "CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer," *Molecular Carcinogenesis*, vol. 34, no. 4, pp. 187–198, 2002.
- [134] R. Stoehr, R. C. Krieg, R. Knuechel et al., "No evidence for involvement of beta-catenin and APC in urothelial carcinomas," *International Journal of Oncology*, vol. 20, no. 5, pp. 905–911, 2002.
- [135] K. M. Rieger-Christ, J. W. Cain, J. W. Braasch et al., "Expression of classic cadherins type I in urothelial neoplastic progression," *Human Pathology*, vol. 32, no. 1, pp. 18–23, 2001.
- [136] R. T. Bryan, P. A. Atherfold, Y. Yeo et al., "Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies," *Journal of Pathology*, vol. 215, no. 2, pp. 184–194, 2008.
- [137] R. T. Bryan and C. Tselepis, "Cadherin switching and bladder cancer," *Journal of Urology*, vol. 184, no. 2, pp. 423–431, 2010.
- [138] C. Tselepis, M. Chidgey, A. North, and D. Garrod, "Desmosomal adhesion inhibits invasive behavior," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 14, pp. 8064–8069, 1998.
- [139] I. G. Conn, M. J. Vilela, D. R. Garrod, J. Crocker, and D. M. A. Wallace, "Immunohistochemical staining with monoclonal antibody 32-2B to desmosomal glycoprotein 1: its role in the histological assessment of urothelial carcinomas," *British Journal of Urology*, vol. 65, no. 2, pp. 176–180, 1990.

- [140] B. Boyer, G. C. Tucker, A. M. Valles, W. W. Franke, and J. P. Thiery, "Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells," *Journal of Cell Biology*, vol. 109, no. 4, part 1, pp. 1495–1509, 1989.
- [141] G. Davies, W. G. Jiang, and M. D. Mason, "Cell-cell adhesion molecules and their associated proteins in bladder cancer cells and their role in mitogen induced cell-cell dissociation and invasion," *Anticancer Research*, vol. 19, no. 1 A, pp. 547–552, 1999.
- [142] D. Naor, R. V. Sionov, and D. Ish-Shalom, "CD44: structure, function, and association with the malignant process," *Advances in Cancer Research*, vol. 71, pp. 241–319, 1997.
- [143] J. Southgate, L. K. Trejdosiewicz, B. Smith, and P. J. Selby, "Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines," *International Journal of Cancer*, vol. 62, no. 4, pp. 449–456, 1995.
- [144] P. Lipponen, S. Aaltoma, V. M. Kosma, M. Ala-Opas, and M. Eskelinen, "Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up," *Journal of Pathology*, vol. 186, no. 2, pp. 157–164, 1998.
- [145] H. Kanayama, "Matrix metalloproteinases and bladder cancer," *The Journal of Medical Investigation*, vol. 48, no. 1-2, pp. 31–43, 2001.
- [146] J. E. Nutt, J. K. Mellon, K. Qureshi, and J. Lunec, "Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours," *British Journal of Cancer*, vol. 78, no. 2, pp. 215–220, 1998.
- [147] K. K. Saran, D. Gould, C. J. Godec, and R. S. Verma, "Genetics of bladder cancer," *Journal of Molecular Medicine*, vol. 74, no. 8, pp. 441–445, 1996.
- [148] M. A. Knowles, P. A. Elder, M. Williamson, J. P. Cairns, M. E. Shaw, and M. G. Law, "Allelotype of human bladder cancer," *Cancer Research*, vol. 54, no. 2, pp. 531–538, 1994.
- [149] C. D. Hurst, H. Fiegler, P. Carr, S. Williams, N. P. Carter, and M. A. Knowles, "High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization," *Oncogene*, vol. 23, no. 12, pp. 2250–2263, 2004.
- [150] M. Castillo-Martin, J. Domingo-Domenech, O. Karni-Schmidt, T. Matos, and C. Cordon-Cardo, "Molecular pathways of urothelial development and bladder tumorigenesis," *Urologic Oncology*, vol. 28, no. 4, pp. 401–408, 2010.
- [151] D. J. McConkey, S. Lee, W. Choi et al., "Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression," *Urologic Oncology*, vol. 28, no. 4, pp. 429–440, 2010.
- [152] M. Nakao, "Epigenetics: interaction of DNA methylation and chromatin," *Gene*, vol. 278, no. 1-2, pp. 25–31, 2001.
- [153] H. Enokida and M. Nakagawa, "Epigenetics in bladder cancer," *International Journal of Clinical Oncology*, vol. 13, no. 4, pp. 298–307, 2008.
- [154] C. Vallot, N. Stransky, I. Bernard-Pierrot et al., "A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression," *Journal of the National Cancer Institute*, vol. 103, no. 1, pp. 47–60, 2011.
- [155] J. W.F. Catto, A. Alcaraz, A. S. Bjartell et al., "MicroRNA in prostate, bladder, and kidney cancer: a systematic review," *European Urology*, vol. 59, no. 5, pp. 671–681, 2011.
- [156] M. J. Bueno, I. P. de Castro, and M. Malumbres, "Control of cell proliferation pathways by microRNAs," *Cell Cycle*, vol. 7, no. 20, pp. 3143–3148, 2008.
- [157] S. Sang, J. D. Lambert, C. -T. Ho, and C. S. Yang, "The chemistry and biotransformation of tea constituents," *Pharmacological Research*, vol. 64, no. 2, pp. 87–99, 2011.
- [158] C. S. Yang, H. Wang, G. X. Li, Z. Yang, F. Guan, and H. Jin, "Cancer prevention by tea: evidence from laboratory studies," *Pharmacological Research*, vol. 64, no. 2, pp. 113–122, 2011.
- [159] C. S. Yang and X. Wang, "Green tea and cancer prevention," *Nutrition and Cancer*, vol. 62, no. 7, pp. 931–937, 2010.
- [160] G. D. Bianchi, J. R. Cerhan, A. S. Parker et al., "Tea consumption and risk of bladder and kidney cancers in a population-based case-control study," *American Journal of Epidemiology*, vol. 151, no. 4, pp. 377–383, 2000.
- [161] J. L. Bushman, "Green tea and cancer in humans: a review of the literature," *Nutrition and Cancer*, vol. 31, no. 3, pp. 151–159, 1998.
- [162] J. V. Higdon and B. Frei, "Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions," *Critical Reviews in Food Science and Nutrition*, vol. 43, no. 1, pp. 89–143, 2003.
- [163] A. Komori, J. Yatsunami, S. Okabe et al., "Anticarcinogenic activity of green tea polyphenols," *Japanese Journal of Clinical Oncology*, vol. 23, no. 3, pp. 186–190, 1993.
- [164] J. K. Kemberling, J. A. Hampton, R. W. Keck, M. A. Gomez, and S. H. Selman, "Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate," *Journal of Urology*, vol. 170, no. 3, pp. 773–776, 2003.
- [165] D. Sato and M. Matsushima, "Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves," *International Journal of Urology*, vol. 10, no. 3, pp. 160–166, 2003.
- [166] E. M. Messing, P. Hanson, P. Ulrich, and E. Erturk, "Epidermal growth factor—interactions with normal and malignant urothelium: in vivo and in situ studies," *Journal of Urology*, vol. 138, no. 5, pp. 1329–1335, 1987.
- [167] Q. Y. Lu, Y. S. Jin, A. Pantuck et al., "Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model," *Clinical Cancer Research*, vol. 11, no. 4, pp. 1675–1683, 2005.
- [168] V. E. Steele, D. Bagheri, D. A. Balentine et al., "Preclinical efficacy studies of green and black tea extracts," *Proceedings of the Society for Experimental Biology and Medicine*, vol. 220, no. 4, pp. 210–212, 1999.
- [169] M. J. Glade, "Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997," *Nutrition*, vol. 15, no. 6, pp. 523–526, 1999.
- [170] D. S. Michaud, D. Spiegelman, S. K. Clinton, E. B. Rimm, W. C. Willett, and E. L. Giovannucci, "Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort," *Journal of the National Cancer Institute*, vol. 91, no. 7, pp. 605–613, 1999.
- [171] J. Nagano, S. Kono, D. L. Preston et al., "Bladder-cancer incidence in relation to vegetable and fruit consumption: a prospective study of atomic-bomb survivors," *International Journal of Cancer*, vol. 86, no. 1, pp. 132–138, 2000.
- [172] D. W. Newling, M. R. Robinson, P. H. Smith et al., "Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder

- cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group," *European Urology*, vol. 27, no. 2, pp. 110–116, 1995.
- [173] S. Banerjee, Y. Li, Z. Wang, and F. H. Sarkar, "Multi-targeted therapy of cancer by genistein," *Cancer Letters*, vol. 269, no. 2, pp. 226–242, 2008.
- [174] M. Messina and S. Barnes, "The role of soy products in reducing risk of cancer," *Journal of the National Cancer Institute*, vol. 83, no. 8, pp. 541–546, 1991.
- [175] L. Yan and E. L. Spitznagel, "Meta-analysis of soy food and risk of prostate cancer in men," *International Journal of Cancer*, vol. 117, no. 4, pp. 667–669, 2005.
- [176] J. R. Zhou, P. Mukherjee, E. T. Gugger, T. Tanaka, G. L. Blackburn, and S. K. Clinton, "Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis," *Cancer Research*, vol. 58, no. 22, pp. 5231–5238, 1998.
- [177] C. L. Sun, J. M. Yuan, X. L. Wang, Y. T. Gao, R. K. Ross, and M. C. Yu, "Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China," *International Journal of Cancer*, vol. 112, no. 2, pp. 319–323, 2004.
- [178] N. P. Gullett, A. R.M. Ruhul Amin, S. Bayraktar et al., "Cancer prevention with natural compounds," *Seminars in Oncology*, vol. 37, no. 3, pp. 258–281, 2010.
- [179] H. Si and D. Liu, "Phytochemical genistein in the regulation of vascular function: new insights," *Current Medicinal Chemistry*, vol. 14, no. 24, pp. 2581–2589, 2007.
- [180] S. J. Su, T. M. Yeh, H. Y. Lei, and N. H. Chow, "The potential of soybean foods as a chemoprevention approach for human urinary tract cancer," *Clinical Cancer Research*, vol. 6, no. 1, pp. 230–236, 2000.
- [181] E. M. Messing and C. A. Reznikoff, "Epidermal growth factor and its receptor: markers of—and targets for—chemoprevention of bladder cancer," *Journal of Cellular Biochemistry*, vol. 50, no. 161, pp. 56–62, 1992.
- [182] D. E. Neal and K. Mellon, "Epidermal growth factor receptor and bladder cancer: a review," *Urologia Internationalis*, vol. 48, no. 4, pp. 365–371, 1992.
- [183] D. Theodorescu, K. R. Laderoute, J. M. Calaoagan, and K. M. Gulding, "Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression," *International Journal of Cancer*, vol. 78, no. 6, pp. 775–782, 1998.
- [184] Y. C. Liang, Y. T. Huang, S. H. Tsai, S. Y. Lin-Shiau, C. F. Chen, and J. K. Lin, "Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages," *Carcinogenesis*, vol. 20, no. 10, pp. 1945–1952, 1999.
- [185] P. Akarasereenont, K. Techatraisak, A. Thaworn, and S. Chotewuttakorn, "The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase," *Mediators of Inflammation*, vol. 11, no. 1, pp. 17–22, 2002.
- [186] M. Garland, J. S. Morris, M. J. Stampfer et al., "Prospective study of toenail selenium levels and cancer among women," *Journal of the National Cancer Institute*, vol. 87, no. 7, pp. 497–505, 1995.
- [187] K. J. Helzlsouer, G. W. Comstock, and J. S. Morris, "Selenium, lycopene, α -tocopherol, β -carotene, retinol, and subsequent bladder cancer," *Cancer Research*, vol. 49, no. 21, pp. 6144–6148, 1989.
- [188] J. T. Pinto, C. Qiao, J. Xing et al., "Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine," *Prostate*, vol. 45, no. 4, pp. 304–314, 2000.
- [189] D. L. Lamm and D. R. Riggs, "Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies," *Journal of Nutrition*, vol. 131, no. 3s, pp. 1067S–1070S, 2001.
- [190] T. Key, P. B. Silcocks, G. K. Davey, P. N. Appleby, and D. T. Bishop, "A case-control study of diet and prostate cancer," *British Journal of Cancer*, vol. 76, no. 5, pp. 678–687, 1997.
- [191] E. Dorant, P. A. van den Brandt, and R. A. Goldbohm, "Allium vegetable consumption, garlic supplement intake, and female breast carcinoma incidence," *Breast Cancer Research and Treatment*, vol. 33, no. 2, pp. 163–170, 1995.
- [192] E. Dorant, P. A. van den Brandt, and R. A. Goldbohm, "A prospective cohort study on the relationship between onion and leek consumption, garlic supplement use and the risk of colorectal carcinoma in the Netherlands," *Carcinogenesis*, vol. 17, no. 3, pp. 477–484, 1996.
- [193] E. Dorant, P. A. van den Brandt, and R. A. Goldbohm, "A prospective cohort study on Allium vegetable consumption, garlic supplement use, and the risk of lung carcinoma in the Netherlands," *Cancer Research*, vol. 54, no. 23, pp. 6148–6153, 1994.
- [194] E. Dorant, P. A. van den Brandt, R. A. Goldbohm, and F. Sturmans, "Consumption of onions and a reduced risk of stomach carcinoma," *Gastroenterology*, vol. 110, no. 1, pp. 12–20, 1996.
- [195] E. Riboli, C. A. Gonzalez, G. Lopez-Abente et al., "Diet and bladder cancer in Spain: a multi-centre case-control study," *International Journal of Cancer*, vol. 49, no. 2, pp. 214–219, 1991.
- [196] C. M. Steinmaus, S. Nuñez, and A. H. Smith, "Diet and bladder cancer: a meta-analysis of six dietary variables," *American Journal of Epidemiology*, vol. 151, no. 7, pp. 693–702, 2000.
- [197] V. Radosavljević, S. Janković, J. Marinković, and M. Dokić, "Diet and bladder cancer: a case-control study," *International Urology and Nephrology*, vol. 37, no. 2, pp. 283–289, 2005.
- [198] G. Steineck, U. Hagman, M. Gerhardsson, and S. E. Norell, "Vitamin a supplements, fried foods, fat and urothelial cancer. A case-referent study in Stockholm in 1985–87," *International Journal of Cancer*, vol. 45, no. 6, pp. 1006–1011, 1990.
- [199] S. M. Cohen, J. F. Wittenberg, and G. T. Bryan, "Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N [4 (5 nitro 2 furyl) 2 thiazolyl]formamide," *Cancer Research*, vol. 36, no. 7, part 1, pp. 2334–2339, 1976.
- [200] M. B. Sporn, R. A. Squire, C. C. Brown et al., "13 cis Retinoic acid: inhibition of bladder carcinogenesis in the rat," *Science*, vol. 195, no. 4277, pp. 487–489, 1977.
- [201] T. Kakizoe, "Chemoprevention of cancer—focusing on clinical trials," *Japanese Journal of Clinical Oncology*, vol. 33, no. 9, pp. 421–442, 2003.
- [202] M. Eichholzer, H. B. Stähelin, K. F. Gey, E. Lüdin, and F. Bernasconi, "Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the

- prospective Basel study," *International Journal of Cancer*, vol. 66, no. 2, pp. 145–150, 1996.
- [203] M. P. Zeegers, E. Kellen, F. Buntinx, and P. A. van den Brandt, "The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review," *World Journal of Urology*, vol. 21, no. 6, pp. 392–401, 2004.
- [204] G. R. Prout Jr. and B. A. Barton, "13-cis-retinoid acid in chemoprevention of superficial bladder cancer," *Journal of Cellular Biochemistry*, vol. 50, no. 161, pp. 148–152, 1992.
- [205] J. L. Clifford, A. L. Sabichi, C. Zou et al., "Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer," *Cancer Epidemiology Biomarkers and Prevention*, vol. 10, no. 4, pp. 391–395, 2001.
- [206] U. E. Studer, S. Jenzer, C. Biedermann et al., "Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland," *European Urology*, vol. 28, no. 4, pp. 284–290, 1995.
- [207] A. L. Sabichi, S. P. Lerner, E. N. Atkinson et al., "Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer," *Clinical Cancer Research*, vol. 14, no. 1, pp. 224–229, 2008.
- [208] A. L. Sabichi, S. P. Lerner, H. B. Grossman, and S. M. Lippman, "Retinoids in the chemoprevention of bladder cancer," *Current Opinion in Oncology*, vol. 10, no. 5, pp. 479–484, 1998.
- [209] D. Byar and C. Blackard, "Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer," *Urology*, vol. 10, no. 6, pp. 556–561, 1977.
- [210] J. U. Schlegel, "Proposed uses of ascorbic acid in prevention of bladder carcinoma," *Annals of the New York Academy of Sciences*, vol. 258, pp. 432–437, 1975.
- [211] A. M. Y. Nomura, L. N. Kolonel, J. H. Hankin, and C. N. Yoshizawa, "Dietary factors in cancer of the lower urinary tract," *International Journal of Cancer*, vol. 48, no. 2, pp. 199–205, 1991.
- [212] D. S. Michaud, D. Spiegelman, S. K. Clinton, E. B. Rimm, W. C. Willett, and E. Giovannucci, "Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men," *American Journal of Epidemiology*, vol. 152, no. 12, pp. 1145–1153, 2000.
- [213] S. Fukushima, K. Imaida, T. Sakata et al., "Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats," *Cancer Research*, vol. 43, no. 9, pp. 4454–4457, 1983.
- [214] K. Wróblewski, "Can the administration of large doses of vitamin C have a harmful effect?" *Polski Merkuriusz Lekarski*, vol. 19, no. 112, pp. 600–603, 2005.
- [215] W. R. Beisel, R. Edelman, K. Nauss, and R. M. Suskind, "Single-nutrient effects on immunologic functions. Report of a workshop sponsored by the Department of Food and Nutrition and its nutrition advisory group of the American Medical Association," *Journal of the American Medical Association*, vol. 245, no. 1, pp. 53–58, 1981.
- [216] E. J. Jacobs, A. K. Henion, P. J. Briggs et al., "Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women," *American Journal of Epidemiology*, vol. 156, no. 11, pp. 1002–1010, 2002.
- [217] D. Albanes, O. P. Heinonen, J. K. Huttunen et al., "Effects of α -tocopherol and β -carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study," *American Journal of Clinical Nutrition*, vol. 62, no. 6, pp. 1427S–1430S, 1995.
- [218] E. R. Miller Jr., R. Pastor-Barriuso, D. Dalal, R. A. Riemersma, L. J. Appel, and E. Guallar, "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality," *Annals of Internal Medicine*, vol. 142, no. 1, pp. 37–46, 2005.
- [219] "The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group," *New England journal of medicine*, vol. 330, no. 15, pp. 1029–1035, 1994.
- [220] E. Okajima, M. Tsutsumi, S. Ozono et al., "Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl)nitrosamine initiation," *Japanese Journal of Cancer Research*, vol. 89, no. 1, pp. 22–26, 1998.
- [221] M. Maggiora, M. Bologna, M. P. Cerù et al., "An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines," *International Journal of Cancer*, vol. 112, no. 6, pp. 909–919, 2004.
- [222] Y. S. Oh, H. S. Lee, H. J. Cho, S. G. Lee, K. C. Jung, and J. H. Y. Park, "Conjugated linoleic acid inhibits DNA synthesis and induces apoptosis in TSU-Pr1 human bladder cancer cells," *Anticancer Research*, vol. 23, no. 6 C, pp. 4765–4772, 2003.
- [223] G. M. Williams, T. Tanaka, H. Maruyama, Y. Maera, J. H. Weisburger, and E. Zang, "Modulation by butylated hydroxytoluene of liver and bladder carcinogenesis induced by chronic low-level exposure to 2-acetylaminofluorene," *Cancer Research*, vol. 51, no. 23, part 1, pp. 6224–6230, 1991.
- [224] T. Tanaka, Y. Morishita, M. Suzui, T. Kojima, A. Okumura, and H. Mori, "Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin," *Carcinogenesis*, vol. 15, no. 1, pp. 15–19, 1994.
- [225] Y. Hirose, T. Tanaka, T. Kawamori et al., "Chemoprevention of urinary bladder carcinogenesis by the natural phenolic compound protocatechuic acid in rats," *Carcinogenesis*, vol. 16, no. 10, pp. 2337–2342, 1995.
- [226] M. Yang, T. Tanaka, Y. Hirose, T. Deguchi, H. Mori, and Y. Kawada, "Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice," *International Journal of Cancer*, vol. 73, no. 5, pp. 719–724, 1997.
- [227] P. Q. Vinh, S. Sugie, T. Tanaka et al., "Chemopreventive effects of a flavonoid antioxidant silymarin on N-Butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice," *Japanese Journal of Cancer Research*, vol. 93, no. 1, pp. 42–49, 2002.
- [228] S. Sugie, P. Q. Vinh, K. M. W. Rahman et al., "Suppressive effect of 1,4-phenylene diisothiocyanate on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice," *International Journal of Cancer*, vol. 117, no. 4, pp. 524–530, 2005.
- [229] K. Miyazawa, S. Miyamoto, R. Suzuki et al., "Dietary beta-cryptoxanthin inhibits N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice," *Oncology Reports*, vol. 17, no. 2, pp. 297–304, 2007.
- [230] Y. Homma, S. Ozono, I. Numata, J. Seidenfeld, and R. Oyasu, "Inhibition of carcinogenesis by alpha-difluoromethylornithine in heterotopically transplanted rat urinary bladders," *Cancer Research*, vol. 45, no. 2, pp. 648–652, 1985.

- [231] C. L. Loprinzi, E. M. Messing, J. R. O'Fallon et al., "Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials," *Cancer Epidemiology Biomarkers and Prevention*, vol. 5, no. 5, pp. 371–374, 1996.
- [232] E. M. Messing, R. R. Love, K. D. Tutsch et al., "Low-dose difluoromethylornithine and polyamine levels in human prostate tissue," *Journal of the National Cancer Institute*, vol. 91, no. 16, pp. 1416–1417, 1999.
- [233] E. Messing, K. M. Kim, F. Sharkey et al., "Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer," *Journal of Urology*, vol. 176, no. 2, pp. 500–504, 2006.
- [234] K. V. N. Rao, C. J. Detrisac, V. E. Steele, E. T. Hawk, G. J. Kelloff, and D. L. McCormick, "Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder," *Carcinogenesis*, vol. 17, no. 7, pp. 1435–1438, 1996.
- [235] M. J. Thun, M. M. Nambodiri, E. E. Calle, W. D. Flanders, and C. W. Heath Jr., "Aspirin use and risk of fatal cancer," *Cancer Research*, vol. 53, no. 6, pp. 1322–1327, 1993.
- [236] J. E. Castela, J. M. Yuan, M. Gago-Dominguez, M. C. Yu, and R. K. Ross, "Non-steroidal anti-inflammatory drugs and bladder cancer prevention," *British Journal of Cancer*, vol. 82, no. 7, pp. 1364–1369, 2000.
- [237] M. S. Linet, W. H. Chow, J. K. McLaughlin et al., "Analgesics and cancers of the renal, pelvis and ureter," *International Journal of Cancer*, vol. 62, no. 1, pp. 15–18, 1995.
- [238] W. Kitayama, A. Denda, E. Okajima, T. Tsujiuchi, and Y. Konishi, "Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine," *Carcinogenesis*, vol. 20, no. 12, pp. 2305–2310, 1999.
- [239] C. J. Grubbs, R. A. Lubet, A. T. Koki et al., "Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats," *Cancer Research*, vol. 60, no. 20, pp. 5599–5602, 2000.
- [240] J. Gee, I. L. Lee, D. Jendiroba, S. M. Fischer, H. B. Grossman, and A. L. Sabichi, "Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer," *Oncology Reports*, vol. 15, no. 2, pp. 471–477, 2006.
- [241] A. Ristimäki, O. Nieminen, K. Saukkonen, K. Hotakainen, S. Nordling, and C. Haglund, "Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder," *American Journal of Pathology*, vol. 158, no. 3, pp. 849–853, 2001.
- [242] T. Shirahama, "Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder," *Clinical Cancer Research*, vol. 6, no. 6, pp. 2424–2430, 2000.
- [243] S. F. Shariat, J. H. Kim, G. E. Ayala, K. Kho, T. M. Wheeler, and S. P. Lerner, "Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder," *Journal of Urology*, vol. 169, no. 3, pp. 938–942, 2003.
- [244] S. P. Lerner, "Bladder cancer clinical trials," *Urologic Oncology*, vol. 23, no. 4, pp. 275–279, 2005.
- [245] R. S. Bresalier, R. S. Sandler, H. Quan et al., "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial," *New England Journal of Medicine*, vol. 352, no. 11, pp. 1092–1102, 2005.
- [246] A. M. Kamat and G. M. Nelkin, "Atorvastatin: a potential chemopreventive agent in bladder cancer," *Urology*, vol. 66, no. 6, pp. 1209–1212, 2005.
- [247] B. A. Ruggeri, C. Robinson, T. Angeles, J. Wilkinson, and M. L. Clapper, "The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth," *Clinical Cancer Research*, vol. 8, no. 1, pp. 267–274, 2002.
- [248] K. J. Helzlsouer and T. W. Kensler, "Cancer chemoprotection by oltipraz: experimental and clinical considerations," *Preventive Medicine*, vol. 22, no. 5, pp. 783–795, 1993.
- [249] T. W. Kensler, T. J. Curphey, Y. Maxiutenko, and B. D. Roebuck, "Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiols," *Drug Metabolism and Drug Interactions*, vol. 17, no. 1–4, pp. 3–22, 2000.
- [250] T. W. Kensler and K. J. Helzlsouer, "Oltipraz: clinical opportunities for cancer chemoprevention," *Journal of Cellular Biochemistry*, vol. 58, no. 22, pp. 101–107, 1995.
- [251] Z. Xiao, T. J. McCallum, K. M. Brown et al., "Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model," *British Journal of Cancer*, vol. 81, no. 4, pp. 638–646, 1999.
- [252] P. A. Oliveira, A. Colaco, P. L. De la Cruz, and C. Lopes, "Rat and mouse urothelial carcinogenesis," *Experimental Pathology and Health Sciences*, vol. 2, pp. 23–28, 2008.
- [253] E. Kunze and J. Chowanec, "Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the urinary bladder," *IARC Scientific Publications*, no. 99, pp. 345–397, 1990.
- [254] T. Tanaka, W. S. Barnes, G. M. Williams, and J. H. Weisburger, "Multipotential carcinogenicity of the fried food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline in rats," *Japanese Journal of Cancer Research*, vol. 76, no. 7, pp. 570–576, 1985.
- [255] P. A. Oliveira, C. Palmeira, L. M. Lourenço, and C. A. Lopes, "Evaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine," *Journal of Experimental and Clinical Cancer Research*, vol. 24, no. 4, pp. 609–616, 2005.
- [256] E. Kunze, A. Schauer, and S. Schatt, "Stages of transformation in the development of N butyl N (4 hydroxybutyl) nitrosamine induced transitional cell carcinomas in the urinary bladder of rats," *Zeitschrift für Krebsforschung und Klinische Onkologie*, vol. 87, no. 2, pp. 139–160, 1976.
- [257] C. Janzowski, D. Jacob, I. Henn, H. Zankl, B. L. Poole-Zobel, and G. Eisenbrand, "Investigations on organ-specific metabolism and genotoxic effects of the urinary bladder carcinogen N-nitrosobutyl-3-carboxypropylamine (BCPN) and its analogs N-nitrosodibutylamine (NDBA) and N-nitrosobutyl-4-hydroxybutylamine (4-OH-NDBA)," *Toxicology*, vol. 59, no. 2, pp. 195–209, 1989.
- [258] M. Hirose, S. Fukushima, and M. Hananouchi, "Different susceptibilities of the urinary bladder epithelium of animal species to three nitroso compounds," *Gann*, vol. 67, no. 2, pp. 175–189, 1976.
- [259] S. M. Cohen, R. E. Greenfield, and G. H. Friedell, "Urinary bladder carcinogenesis," *Pathobiology Annual*, vol. 12, pp. 267–280, 1982.
- [260] N. Ito and S. Fukushima, "Promotion of urinary bladder carcinogenesis in experimental animals," *Experimental Pathology*, vol. 36, no. 1, pp. 1–15, 1989.

Review

Cancer Chemopreventive Ability of Conjugated Linolenic Acids

Takuji Tanaka ^{1,*}, Masashi Hosokawa ², Yumiko Yasui ³, Rikako Ishigamori ⁴ and Kazuo Miyashita ⁵

¹ The Tohkai Cytopathology Institute: Cancer Research and Prevention (TCI-CaRP), 5-1-2 Minami-uzura, Gifu 500-8285, Japan

² Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato-cho, Hakodate, Hokkaido 041-8611, Japan; E-Mail: hosoo@fish.hokudai.ac.jp

³ School of Veterinary Medicine, Rakuno Gakuen University, 582 Midorimachi, Bunkyo-dai, Ebetsu, Hokkaido 069-8501, Japan; E-Mail: y-yasui@rakuno.ac.jp

⁴ Division of Cancer Development System, Carcinogenesis Research Group, National Cancer Research Institute, Chuo-ku, Tokyo 104-0045, Japan; E-Mail: rishigam@ncc.go.jp

⁵ Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minato-cho, Hakodate, Hokkaido 041-8611, Japan; E-Mail: kmiya@fish.hokudai.ac.jp

* Author to whom correspondence should be addressed; E-Mail: takutt@toukaisaibou.co.jp; Tel.: +81-58-273-4399; Fax: +81-58-273-4392.

Received: 19 August 2011; in revised form: 12 October 2011 / Accepted: 25 October 2011 / Published: 2 November 2011

Abstract: Conjugated fatty acids (CFA) have received increased interest because of their beneficial effects on human health, including preventing cancer development. Conjugated linoleic acids (CLA) are such CFA, and have been reviewed extensively for their multiple biological activities. In contrast to other types of CFAs including CLA that are found at low concentrations (less than 1%) in natural products, conjugated linolenic acids (CLN) are the only CFAs that occur in higher quantities in natural products. Some plant seeds contain a considerably high concentration of CLN (30 to 70 wt% lipid). Our research group has screened CLN from different plant seed oils to determine their cancer chemopreventive ability. This review describes the physiological functions of CLN isomers that occur in certain plant seeds. CLN are able to induce apoptosis through decrease of Bcl-2 protein in certain human cancer cell lines, increase expression of peroxisome proliferator-activated receptor (PPAR)- γ , and up-regulate gene expression of p53. Findings in our preclinical animal studies have indicated that feeding with CLN resulted in inhibition of colorectal tumorigenesis through modulation of apoptosis and expression of PPAR γ and p53. In this

review, we summarize chemopreventive efficacy of CLN against cancer development, especially colorectal cancer.

Keywords: CLN; CLA; plant seed oils; cancer chemoprevention; PPAR γ ; p53

1. Introduction

Several fatty acids with conjugated double bonds are present in nature. These conjugated fatty acids (CFA) include conjugated dienes, trienes, and tetraenes. Examples are edible fats of ruminant origin, such as milk fat, tallow that contain conjugated linoleic acids (CLA) [1]. Many plant seed oils also contain conjugated trienoic fatty acids in the form of conjugated linolenic acids (CLN) [2,3]. In addition, aquatic plants including seaweeds contain conjugated polyenes in the forms of conjugated eicosapentaenoic acid (CEPA) and conjugated arachidonic acid (CAA) [4–6].


Most CFAs are 18-carbon compounds originating from oleic, linoleic, linolenic, and stearidonic acids. They occur in terrestrial plant lipids, especially seed oils, and include dienes, trienes, and tetraenes. The conjugated trienoic fatty acids from plant are mainly α -eleostearic acid (9c,11t,13t-18:3), catalpic acid (9t,11t-13c-18:3), punicic acid (9c,11t,13c-18:3), calendic acid (8t,10t,12c-18:3), and jacaric acid (8c,10t,12c-18:3) [7] (Figure 1). Calendic acid occurs in pot marigold seed oil, punicic acid in pomegranate seed oil, and α -eleostearic acid in tung and bitter gourd seed oils [8]. Main CLN of the plant seed oils are c,t,c, c,t,t, or t,t,c-isomers. Minor fatty acids, β -eleostearic acid (9t,11t,13t-18:3) and β -calendic acid (8t,10t,12t-18:3), are also present in some seed oils [8]. α -Eleostearic acid is the principal component of bitter gourd seed oil by contributing to more than 50% of oil; but the flesh of the bitter gourd contains catalpic acid [9].

A well-known conjugated diene and tetraene of plant origin is 10t 12t-18:2 [10] and α -parinaric acid (9c,11t,13t,15c-18:4) [11,12]. There are no reports on the occurrence of CFA with more than 18 carbon atoms in lipids of plant origin, and the major source of all these conjugated trienoic fatty acids may be seed oils. Most of seed oils contain positional and geometrical isomers of linolenic acid (18:3) with conjugated double bonds that is often referred to CLN. Unlike CLA that occurs at concentrations of less than 1% in nature, extremely high amounts of naturally occurring CLN is present in some seed oils. For example, 62.2% of pot marigold seed oil is calendic acid (8t,10t,12c-18:3), 83% of pomegranate seed oil is punicic acid (9c,11t,13c-18:3), 67.7% of tung seed oil and 56.2% of bitter gourd seed oil is α -eleostearic acid (9c,11t,13t-18:3), and 42.3% of catalpa seed oil is catalpic acid (9t,11t,13c-18:3) [8]. Among seed oils that are sources of CLN, bitter gourd and pomegranate are edible plants, and catalpa is often used as Chinese medicine.

Although the bioactive properties of the CLA isomers have long been recognized [13,14], CLN have recently shown potent bioactivity. In a large number of *in vitro* and *in vivo* studies [15–18], CLN have displayed potent anti-inflammatory, immunomodulatory, anti-obese and anti-carcinogenic activities, along with the ability to improve biomarkers of cardio-vascular health. CLN isomers are naturally present in high concentrations in a large variety of seed oils and can also be produced *in vitro* by strains of lactobacilli and bifidobactera through the activity of the enzyme linoleic acid isomerase on α -linolenic acid [15,19]. In this review, we will summarize our findings in several studies showing

possible cancer chemopreventive activities of CLN against colorectal cancer (CRC) and the mechanisms through which the activities are mediated.

Figure 1. Conjugated linolenic acids (CLN) present in plant seed oils.



2. CLN Inhibits Colon Carcinogenesis *in Vivo* Studies

About 30% of human cancers are considered to be associated with dietary habits and lifestyle. In particular, the amount and type of dietary fat influence development of certain types of cancer, such as colorectal malignancy [20–23]. CRC that is more common in developed countries is the third most commonly diagnosed cancer in the world [24]. In 2008, GLOBOCAN estimated that 1.23 million new cases of CRC were clinically diagnosed and killed more than 600,000 people [24]. It is well-known that CRC is linked to Western lifestyle, which often includes intake of high-fat diets, and the amount

and type of dietary fat consumed are of particular importance for development of CRC [22,25–29]. Epidemiological studies suggest that high intake of fish and fish oil rich in *n*-3 polyunsaturated fatty acids (PUFA) correlates with a reduced risk of colorectal malignancy. Laboratory animal carcinogenesis studies indicate that *n*-3 PUFA are protective, whereas *n*-6 PUFA promote colorectal oncogenesis. The mechanisms of protection by *n*-3 PUFA is mainly due to their interference with biosynthesis of two-series of prostaglandins (PGs) from arachidonic acid [30].

In a short-term animal study, dietary feeding with bitter melon (*Momordica charantia*) seed oil (BGO) for 5 weeks at three dose levels (0.01, 0.1, and 1%) caused a significant reduction in the frequency of colonic aberrant crypt foci (ACF, Figure 2a), which are putative precursor lesions for CRC [31,32], in rats initiated with a colonic carcinogen, azoxymethane (AOM) [33]. A significant reduction in the multiplicity of ACF (Figure 3a) was found in rats fed the diet containing 0.01% BGO, in which 0.006% CLN (9c,11t,13t-18:3) was present. In another experiment, all three dose levels (0.01, 0.1, and 1%) of dietary administration with catalpa (*Catalpa ovata*) seed oil (CPO) that contains a large amount of catalpic acid (9t,11t,13c-18:3) for 5 weeks significantly inhibited ACF formation induced by AOM when compared to rats treated with AOM alone [34] (Figure 3b). Importantly, these studies showed that the diets containing BGO or CPO did not affect normal growth of colonic crypts and histology of liver, such as fatty liver. This may be explained by the findings in another *in vivo* study demonstrating that the BGO-containing diets significantly reduced free cholesterol levels with a trend toward an increase in high density lipoprotein, but did not affect the total cholesterol level [35]. Cell proliferation plays an important role in multistage carcinogenesis with multiple genetic changes. Dietary feeding with BGO or CPO lowered cell proliferation of ACF as well as normal appearing crypts of rats that received AOM, where the lesions and crypts were hyper-proliferation status due to injection of a colonic carcinogen, AOM [33,34]. Other natural compounds [36–38] and retinoids [39] that are potential cancer chemopreventive agents possess similar effects [40–42]. As to the effects of BGO and CPO on apoptosis in the ACF, feeding with BGO or CPO increased apoptotic cells in ACF [33,34]. These findings were consistent with the anti-proliferative and apoptosis-inducing effects of CLN found *in vitro* studies with human colon cancer cell lines [43–45].

In a subsequent long-term *in vivo* assay, we confirmed chemopreventive ability of BGO against CRC development in rats [46]. Dietary administration of BGO rich in CLN (9c,11t,13t-18:3) for 32 weeks significantly lowered the incidence of colonic adenoma (Figure 2b) and adenocarcinoma (Figure 2c) induced by AOM in rats without causing any adverse effects (Figure 4a). The multiplicities (number of adenocarcinoma per rat) of CRC were also reduced when fed the BGO-containing diets at all three dose levels (0.01, 0.1, and 1%) (Figure 4b). Pomegranate (*Punica granatum* L.) seed oil (PGO) rich in other CLN isomer (9c,11t,13c-18:3) that was given to rats in their diet for 32 weeks also inhibited AOM-induced colorectal carcinogenesis, as estimated by the occurrence of colorectal adenocarcinoma (Figure 4c,d) [47]. Although the protective effects of BGO and PGO against CRC development were not dose-dependent, dietary feeding with BGO and PGO during the post-initiation stage suppressed progression of adenoma to malignant epithelial neoplasm (adenocarcinoma) [46,47]. In the long-term *in vivo* studies, we found interesting findings that dietary feeding with BGO or PGO increased expression of peroxisome proliferator-activated receptor (PPAR)- γ expression in the colonic mucosa [46,47]. PPARs that are members of the nuclear receptor superfamily have three different isoforms: PPAR α , PPAR δ , and PPAR γ . PPARs are ligand-activated transcription factors, and they are

implicated in tumor progression, differentiation, and apoptosis. PPAR ligands are reported to activate PPAR signaling and exert cancer prevention and treatment *in vitro* and/or *in vivo* studies [48–50]. The findings are consistent with that *in vitro* studies using human CRC cell lines [44,45], where CLN (9c,11t,13t-18:3) was able to induce apoptosis in human colon cancer cells and enhance PPAR γ expression in the CRC cells. Lipid peroxidation may be another possible explanation for the inhibitory effects of BGO and PGO on colorectal carcinogenesis [51]. Human CRC cells, DLD-1, were inoculated into nude mice, and then they were gavaged with CLA (9c,11t- and 10t,12c-18:2) and CLN (9c,11t,13t-18:3). The CLA and CLN treatments resulted in retardation of tumor growth, and the inhibitory effects of tumor growth was strong in the order of CLN >9c,11t-CLA > 10t,12c-CLA. CLN treatment caused DNA fragmentation and increased lipid peroxidation in tumor cells. Similar findings were observed in other study on the effects of CEPA [52], where CEPA had extremely strong anti-tumor effects on transplanted tumor cells, when compared to CEPA and CLA. In the tumor cells inoculated into the mice, the membranous phospholipid hydroperoxide and thiobarbituric acid reactive substances (TBARS) levels increased, when mice were given CEPA, suggesting the involvement of lipid peroxidation in the anti-carcinogenic effects of CEPA.

Figure 2. Colonic preneoplastic and neoplastic lesions induced by a colonic carcinogen, azoxymethane (AOM). (a) Aberrant crypt foci (ACF, circled) on colonic mucosa stained with methylene blue; (b) Tubular adenoma; (c) Tubular adenocarcinoma. ((a) Methylene blue stain; (b) and (c) Hematoxylin and eosin-stain; Bars: (a) (c) 500 μ m; (b) 200 μ m).




Figure 3. The numbers of aberrant crypt foci (ACF) induced by azoxymethane (AOM) from *in vivo* short-term assays determining the effects of 5-week feeding with (a) Bitter gourd (*Momordica charantia*) seed oil (BGO) and (b) Catalpa (*Catalpa ovata*) seed oil (CPO) in rats.





Figure 4. The incidences and multiplicities of adenocarcinoma (ADC) induced by azoxymethane (AOM) *in vivo* long-term assays determining the effects of 32-week feeding with (a) (b) BGO and (c) (d) PGO in rats. (a) (c) the incidences of ADC; and (b) (d) the multiplicities of ADC.



In vivo experimental animal studies demonstrating that dietary feeding with BGO [33,46], PGO [47], and CPO [34] exerts their chemopreventive activities in rat colorectal carcinogenesis, CLA isomers (9c,11t-18:2 for BGO and PGO; and 9t, 11t-18:2 for CPO) were detected in the liver lipids of rats fed with CLN [35,53]. CLA is a powerful anti-carcinogenesis agent in the rat mammary carcinogenesis with an effective range of 0.1 to 1.0% in the diet [54–56]. Therefore, the potential cancer chemopreventive effects of CLN are considered to be partly due to the presence of CLA isomers derived from CLN. A possible pathway for the formation of CLA in the liver lipids of rats fed BGO, PGO, and CPO is the bioconversion of CLN (9c,11t,13t-18:3, 9c,11t,13c-18:3, and 9t,11t,13c-18:3) to CLA (9c,11t-18:2 and 9t,11t-18:2) [35,53], but this bioconversion has not been confirmed in human. Although this may contribute to the inhibitory effects of CLN on colorectal carcinogenesis, other factors such as direct action of CLN as PPAR γ ligand [46,47] and acceleration of lipid peroxidation followed by apoptosis [51] should be taken into account because powerful cancer chemopreventive activity of CLN at low dose levels was observed in our colorectal carcinogenesis studies [33,46,47]. Also, other mechanisms, including anti-inflammatory action, are considered for the inhibitory effects of CLN on colorectal carcinogenesis [32,48,57].

3. Growth-Inhibitory Effects of CLN *in Vitro* Studies

Naturally occurring CLN inhibit growth of variety of cancer cells and difference in activity was observed among different CLN isomers. Calendic acid (8t,10t,12c-18:3) from pot marigold did not affect the growth of SV-T2, SV40-transformed mouse fibroblasts, but α -eleostearic acid (9c,11t,13t-18:3), catalpic acid (9t,11t,13c-18:3), and puniceic acid (9c,11t,13c-18:3) were cytotoxic to the cells [58]. Similar anti-growth effects of α -eleostearic, catalpic, and puniceic acids were observed in case of human monocytic leukemia cell line, U-937 [58]. Difference in cis/trans configuration among the CLN isomers did not influence their cytotoxic ability. Also, the growth inhibitory effects of each 9,11,13-CLN isomer with either c-t-c, c-t-t or t-t-c configuration was greatly enhanced by adding an antioxidant, butylated hydroxytoluene to fatty acid [58]. This suggests involvement of lipid peroxidation in the cytotoxic effects of 9,11,13-CLN on human cancer cells. The oxidative stabilities of three types of 9,11,13-18:3 isomers were comparable, but was lower than the 8t,10t,12c-18:3 isomer [58]. Therefore, the cytotoxicity of 9,11,13-18:3 that was greater than 8.10,12-18:3 may be partly due to their different susceptibilities to peroxidation [58].

The cytotoxic and anti-growth effects of CLN were also observed other human cancer cell lines, DLD-1 (colorectal adenocarcinoma), HepG2 (well-differentiated hepatocellular carcinoma), A549 (lung alveolar cell carcinoma), and HL-60 (acute promyelocytic leukemia) [51]. A fatty acid mixture rich in CLN (α -eleostearic acid; 9c,11t,13t-18:3) showed dose-dependent growth-inhibitory effects via activation of the apoptotic pathway. The effects on a human CRC cell line (DLD-1) were stronger than two CLA isomers, 9c,11t-18:2 and 10t,12c-18:2. In the assays, the apoptotic promoting factors, caspases were activated by adding of α -eleostearic acid-rich fatty acid mixture to DLD-1 cells. The treatment with the fatty acid mixture resulted in an increase of amounts of membrane phospholipid peroxidation in DLD-1 cells, as measured by the TBARS values. In contrast, addition of α -tocopherol suppressed oxidative stress and apoptosis that were induced by α -eleostearic acid-rich fatty acid mixture.

The mechanisms underlying the cytotoxicity and apoptosis induced by α -eleostearic acid in Caco-2 cells (human colorectal adenocarcinoma) is suspected to be modulation of lipid peroxidation. However, the cytotoxic effects of β -eleostearic acid and β -calendic acid, which have all-trans-conjugated double bonds, were not completely reduced in the presence of α -tocopherol. This may suggest the presence of pathway(s) other than lipid peroxidation in the reduction of cell viability of Caco-2 cells by β -eleostearic and β -calendic acids. On the other hand, the cytotoxic effects of β -eleostearic acid on DLD-1 cells were not observed when α -tocopherol was added. Therefore, the metabolic and signal transduction systems in Caco-2 cells may contribute to different anti-cancer and anti-growth effects among CLN isomers, suggesting that further investigations are required for a better understanding of the specific mechanisms underlying the cytotoxic and apoptosis-inducing effects of β -eleostearic and β -calendic acids.

Major CLN present in the plant seed oils are c,t,c, c,t,t, or t,t,c-isomers. In addition, β -eleostearic acid (9t,11t,13t-18:3) and β -calendic acid (8t,10t,12t-18:3) are also present in some seed oils as minor fatty acids [8]. These all-trans-CLN isomers are contained as mixtures of CLN that are chemosynthesized by alkaline isomerization of linolenic acid [59]. Growth inhibition effects and induction of DNA fragmentation by β -eleostearic acid and β -calendic acids in Caco-2 cells were greater than α -eleostearic and α -calendic acids with cis configuration [43]. Furthermore, down-regulation of an anti-apoptotic protein bcl-2 mRNA and up-regulation of a pro-apoptotic protein bax mRNA in Caco-2 cells by β -eleostearic acid were greater than that by α -eleostearic acid. These findings indicate that the configuration of conjugated double bonds is important in cytotoxicity and apoptosis induced by CLN in Caco-2 cells and all-trans-CLN isomers act as more effective tumor-growth inhibitory compounds. When compared to CLA isomers with cis configuration, the greater tumor-inhibitory and apoptosis-inducing effects by all trans isomer of CLA on human CRC cell lines were demonstrated in a report by Beppu *et al.* [60]. In their study, three different human CRC cell lines, Caco-2, HT-29, and DLD-1, were incubated with 9c,11c-18:2, 9c,11t-18:2, 10t,12c-18:2 or 9t,11t-18:2, the strongest effect was observed in the treatment with 9t,11t-18:2, followed by 10t,12c-18:2, 9c,11c-18:2, and 9c,11t-18:2.

4. Molecular Mechanisms by Which CLN Exert Anti-Carcinogenesis and Anti-Tumor Growth Effects

The anti-carcinogenic effects of CLN and CLA have further been confirmed by Yasui *et al.* [45]. In their study, free fatty acids prepared from BGO (BGO-FFA) containing more than 60% α -eleostearic acid (9c,11t,13t-18:3) exhibited strong tumor-growth inhibition and apoptosis induction in three human CRC cell lines, DLD-1, HT-29, and Caco-2, the effects being greater than CLA (9c,11t-18:2). The study also demonstrated that the inhibitory effects of CLN were associated with modulation of PPAR- γ expression, which is one of the target molecules for suppressing development of cancer and other chronic diseases [48–50,61,62]. The treatment with BGO-FFA in Caco-2 cells resulted in approximately 3-fold increase in the expression of PPAR γ protein in a dose-dependent manner, which was greater than an increase (1.5-fold) by troglitazone [45]. Cancer-retardant activity of CLA has also been reported to be associated with its ability to activate PPAR γ [63]. PPAR γ is predominantly found in normal adipose tissue [64], but is also expressed in cancer cells developed in a variety of tissues, including colorectum [65,66], breast [67], prostate [68], and tongue [69]. PPAR γ

activation induces growth arrest and apoptosis in CRC [70,71] and breast cancer cell lines [72]. In experimental colorectal carcinogenesis, a specific PPAR γ ligand, troglitazone, effectively suppresses the development of ACF initiated with AOM and promoted with dextran sodium sulfate in rats [50,73]. PPAR γ ligands, such as troglitazone and 15-deoxy-delta12,14-prostaglandin J2 (15-d-PGJ2), cause growth-inhibition and induction of apoptosis in human cancer cell lines [71,72,74].

In another study by Yasui *et al.*, the effects (reduction of cell viability and apoptosis induction) of CLN (9c,11t,13t-18:3) on the growth of HT-29 cells were much greater than that found in Caco-2 cells [44]. In general, expression of the PPAR γ protein in HT-29 and DLD-1 cells is higher than that of Caco-2 cells. Therefore, 9c,11t,13t-18:3 as well as troglitazone are more effective in growth inhibition and apoptosis induction of CRC cells with highly expressed PPAR γ protein. HT-29, Caco-2, and DLD-1 cells are poorly differentiated, well-differentiated moderately differentiated adenocarcinomas, respectively [75,76]. Combination treatments with irinotecan and 5-fluorouracil resulted in different anti-cancer effect among CRC cell lines [77]. The differential responses of 9c,11t,13t-18:3 and troglitazone against HT-29, Caco-2 and DLD-1 cell lines may be depend on differences in cell differentiation of adenocarcinoma cells and PPAR γ expression level.

The p53, growth-arrest, and GADD45 play important roles in the pathways of growth-inhibition and apoptosis induction in a variety of cancer cells [78,79]. Interestingly, the up-regulation of growth arrest and of DNA damage-inducible gene, GADD45, was observed in Caco-2 cells that received BGO-FFA [45]. Up-regulation of GADD45 mRNA in the Caco-2 cells treated with BGO-FFA was induced in a dose-dependent manner [45]. Up-regulation of p53 mRNA was also observed in Caco-2 cells treated with BGO-FFA [45]. Takekawa and Saito [80] identified GADD45 as a critical mediator of apoptosis triggered by the activation of JNK and/or p38, via MTK1/MEKK4 MAPK signaling pathways. GADD45 is also a target gene induced by the p53 tumor suppressor [81]. Although down-stream signaling from GADD45 that is affected by BGO-FFA is still unknown, we suspected that up-regulation of GADD45 and p53 contributes to apoptosis induction in Caco-2 cells treated with BGO-FFA.

5. Conclusion and Future Perspectives

CFA, such as CLA, CLN, and other polyenoic fatty acids, are indisputably reported to be novel biomolecules possessing potential health benefits, but it generally only occurs in very low quantities (<1%) in products of natural origin. The fact that high amounts of naturally occurring CLN are present in certain plant seed oils suggests it is much more accessible and easily available for dietary use than previously thought. CLN is thus a CFA with potential use as a functional food component in nutraceuticals. However, increased interest in CLN as a potential biomolecule and multi-biological function should be corroborated with information on its oxidative stability. In conclusion, CLN has a great potential as an ingredient in functional and health food formulations. Further, the exact biological effects CLN on the pathophysiological systems must be established in respect to its oxidative stability, since CLN is more susceptible to oxidation than corresponding non-conjugated fatty acid, α -linolenic acid [58]. Also, safety of CLN in humans [82–84] should be confirmed if CLN is to be used as a nutraceutical.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgments

This review was based on studies supported in part by a Grant-in-Aid for the 3rd Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan; a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research (Nos. 18592076, 17015016 and 18880030) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and a grant (H2010-12) for the Project Research from High-Technology Center of Kanazawa Medical University.

References

1. Chin, S.F.; Liu, W.; Storkson, J.M.; Ha, Y.L.; Pariza, M.W. Dietary sources of conjugated dienoic isomers of linoleic acid, a newly recognized class of anticarcinogens. *J. Food Comp. Anal.* **1992**, *5*, 185–197.
2. Chisholm, M.J.; Hopkins, C.Y. Conjugated fatty acids in some cucurbitaceae seed oils. *Can. J. Biochem.* **1967**, *45*, 1081–1086.
3. Liu, L.; Hammond, E.G.; Nikolau, B.J. *In vivo* studies of the biosynthesis of [alpha]-eleostearic acid in the seed of *Momordica charantia* L. *Plant Physiol.* **1997**, *113*, 1343–1349.
4. Bhaskar, N.; Kinami, T.; Miyashita, K.; Park, S.B.; Endo, Y.; Fujimoto, K. Occurrence of conjugated polyenoic fatty acids in seaweeds from the Indian Ocean. *Z. Naturforsch. C* **2004**, *59*, 310–314.
5. Lopez, A.; Gerwick, W.H. Two new icosapentaenoic acids from the temperate red seaweed *Ptilota filicina* J. Agardh. *Lipids* **1987**, *22*, 190–194.
6. Wise, M.L.; Hamberg, M.; Gerwick, W.H. Biosynthesis of conjugated triene-containing fatty acids by a novel isomerase from the red marine alga *Ptilota filicina*. *Biochemistry* **1994**, *33*, 15223–15232.
7. Hildebrand, D.F. Plant lipid biochemistry: Occurrence or unusual fatty acids in plants. 2010. Available online: <http://lipidlibrary.aocs.org/plantbio/unusualfa/index.htm> (accessed on 29 July 2011).
8. Takagi, T.; Itabashi, Y. Occurrence of mixtures of geometrical isomers of conjugated octadecatrienoic acids in some seed oils: Analysis by open tubular gas liquid chromatography and high performance liquid chromatography. *Lipids* **1981**, *16*, 546–551.
9. Suzuki, R.; Arato, S.; Noguchi, R.; Miyashita, K.; Tachikawa, O. Occurrence of conjugated linolenic acid in flesh and seed of bitter melon. *J. Oleo Sci.* **2001**, *50*, 753–758.
10. Hopkins, C.Y.; Chisholm, M.J. Isolation of natural isomer of linoleic acid from seed oil. *J. Am. Oil Chem. Soc.* **1964**, *41*, 42–44.
11. Bagby, M.O.; Smith, C.R., Jr.; Wolff, I.A. Stereochemistry of alpha-parinaric acid from *impatiens edgeworthii* seed oil. *Lipids* **1966**, *1*, 263–267.

12. Spitzer, V.; Marx, F.; Pfeilsticker, K. Electron impact mass spectra of the oxazoline derivatives of some conjugated diene and triene C18 fatty acids. *J. Am. Oil Chem. Soc.* **1994**, *71*, 873–876.
13. Kelley, N.S.; Hubbard, N.E.; Erickson, K.L. Conjugated linoleic acid isomers and cancer. *J. Nutr.* **2007**, *137*, 2599–2607.
14. Reynolds, C.M.; Roche, H.M. Conjugated linoleic acid and inflammatory cell signalling. *Prostaglandins Leukot. Essent. Fatty Acids* **2010**, *82*, 199–204.
15. Hennessy, A.A.; Ross, R.P.; Devery, R.; Stanton, C. The health promoting properties of the conjugated isomers of alpha-linolenic acid. *Lipids* **2011**, *46*, 105–119.
16. Koba, K.; Akahoshi, A.; Yamasaki, M.; Tanaka, K.; Yamada, K.; Iwata, T.; Kamegai, T.; Tsutsumi, K.; Sugano, M. Dietary conjugated linolenic acid in relation to CLA differently modifies body fat mass and serum and liver lipid levels in rats. *Lipids* **2002**, *37*, 343–350.
17. Miranda, J.; Fernandez-Quintela, A.; Macarulla, M.T.; Churruga, I.; Garcia, C.; Rodriguez, V.M.; Simon, E.; Portillo, M.P. A comparison between CLNA and CLA effects on body fat, serum parameters and liver composition. *J. Physiol. Biochem.* **2009**, *65*, 25–32.
18. Nerurkar, P.; Ray, R.B. Bitter melon: antagonist to cancer. *Pharm. Res.* **2010**, *27*, 1049–1053.
19. Boussetta, T.; Raad, H.; Letteron, P.; Gougerot-Pocidallo, M.A.; Marie, J.C.; Driss, F.; El-Benna, J. Punicic acid a conjugated linolenic acid inhibits TNFalpha-induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. *PLoS One* **2009**, *4*, doi:10.1371/journal.pone.0006458.
20. Bartsch, H.; Nair, J.; Owen, R.W. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. *Carcinogenesis* **1999**, *20*, 2209–2218.
21. Rao, C.V.; Hirose, Y.; Indranie, C.; Reddy, B.S. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. *Cancer Res.* **2001**, *61*, 1927–1933.
22. Reddy, B.S.; Tanaka, T.; Simi, B. Effect of different levels of dietary trans fat or corn oil on azoxymethane-induced colon carcinogenesis in F344 rats. *J. Natl. Cancer Inst.* **1985**, *75*, 791–798.
23. Wynder, E.L.; Kajitani, T.; Ishikawa, S.; Dodo, H.; Takano, A. Environmental factors of cancer of the colon and rectum. II. Japanese epidemiological data. *Cancer* **1969**, *23*, 1210–1220.
24. International Agency for Research on Cancer. Available online: <http://globocan.iarc.fr/factsheets/cancers/colorectal.asp>. (accessed on 29 July 2011).
25. Alexander, D.D.; Cushing, C.A. Red meat and colorectal cancer: A critical summary of prospective epidemiologic studies. *Obes. Res.* **2011**, *12*, e472–e493.
26. Center, M.M.; Jemal, A.; Smith, R.A.; Ward, E. Worldwide variations in colorectal cancer. *CA Cancer J. Clin.* **2009**, *59*, 366–378.
27. Chan, A.T.; Giovannucci, E.L. Primary prevention of colorectal cancer. *Gastroenterology* **2010**, *138*, 2029–2043.
28. Herszenyi, L.; Tulassay, Z. Epidemiology of gastrointestinal and liver tumors. *Eur. Rev. Med. Pharmacol. Sci.* **2010**, *14*, 249–258.
29. Le Marchand, L.; Wilkens, L.R.; Kolonel, L.N.; Hankin, J.H.; Lyu, L.C. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. *Cancer Res.* **1997**, *57*, 4787–4794.
30. Reddy, B.S. Dietary fat and colon cancer: animal model studies. *Lipids* **1992**, *27*, 807–813.

31. Rosenberg, D.W.; Giardina, C.; Tanaka, T. Mouse models for the study of colon carcinogenesis. *Carcinogenesis* **2009**, *30*, 183–196.
32. Tanaka, T. Colorectal carcinogenesis: Review of human and experimental animal studies. *J. Carcinog.* **2009**, *8*, doi:10.4103/1477-3163.49014.
33. Kohno, H.; Suzuki, R.; Noguchi, R.; Hosokawa, M.; Miyashita, K.; Tanaka, T. Dietary conjugated linolenic acid inhibits azoxymethane-induced colonic aberrant crypt foci in rats. *Jpn. J. Cancer Res.* **2002**, *93*, 133–142.
34. Suzuki, R.; Yasui, Y.; Kohno, H.; Miyamoto, S.; Hosokawa, M.; Miyashita, K.; Tanaka, T. Catalpa seed oil rich in 9t,11t,13c-conjugated linolenic acid suppresses the development of colonic aberrant crypt foci induced by azoxymethane in rats. *Oncol. Rep.* **2006**, *16*, 989–996.
35. Noguchi, R.; Yasui, Y.; Suzuki, R.; Hosokawa, M.; Fukunaga, K.; Miyashita, K. Dietary effects of bitter gourd oil on blood and liver lipids of rats. *Arch. Biochem. Biophys.* **2001**, *396*, 207–212.
36. Kohno, H.; Maeda, M.; Honjo, S.; Murakami, M.; Shimada, R.; Masuda, S.; Sumida, T.; Azuma, Y.; Ogawa, H.; Tanaka, T. Prevention of colonic preneoplastic lesions by the beta-cryptoxanthin and hesperidin rich powder prepared from Citrus Unshiu Marc. Juice in male F344 rats. *J. Toxicol. Pathol.* **1999**, *12*, 209–215.
37. Tanaka, T.; Kohno, H.; Shimada, R.; Kagami, S.; Yamaguchi, F.; Kataoka, S.; Ariga, T.; Murakami, A.; Koshimizu, K.; Ohigashi, H. Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats. *Carcinogenesis* **2000**, *21*, 1183–1189.
38. Tanaka, T.; Shimizu, M.; Kohno, H.; Yoshitani, S.; Tsukio, Y.; Murakami, A.; Safitri, R.; Takahashi, D.; Yamamoto, K.; Koshimizu, K.; *et al.* Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from *Zingiber zerumbet*. *Life Sci.* **2001**, *69*, 1935–1945.
39. Zheng, Y.; Kramer, P.M.; Olson, G.; Lubet, R.A.; Steele, V.E.; Kelloff, G.J.; Pereira, M.A. Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. *Carcinogenesis* **1997**, *18*, 2119–2125.
40. Tanaka, T.; Miyamoto, S.; Suzuki, R.; Yasui, Y. Chemoprevention of colon carcinogenesis by dietary non-nutritive compounds. *Curr. Topics Nutraceut. Res.* **2006**, *4*, 127–152.
41. Tanaka, T.; Oyama, T.; Yasui, Y. Dietary supplements and colorectal cancer. *Curr. Topics Nutraceut. Res.* **2008**, *6*, 165–188.
42. Tanaka, T.; Sugie, S. Inhibition of colon carcinogenesis by dietary non-nutritive compounds. *J. Toxicol. Pathol.* **2007**, *20*, 215–235.
43. Yasui, Y.; Hosokawa, M.; Kohno, H.; Tanaka, T.; Miyashita, K. Growth inhibition and apoptosis induction by all-trans-conjugated linolenic acids on human colon cancer cells. *Anticancer Res.* **2006**, *26*, 1855–1860.
44. Yasui, Y.; Hosokawa, M.; Kohno, H.; Tanaka, T.; Miyashita, K. Troglitazone and 9cis,11trans,13trans-conjugated linolenic acid: Comparison of their antiproliferative and apoptosis-inducing effects on different colon cancer cell lines. *Chemotherapy* **2006**, *52*, 220–225.
45. Yasui, Y.; Hosokawa, M.; Sahara, T.; Suzuki, R.; Ohgiya, S.; Kohno, H.; Tanaka, T.; Miyashita, K. Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. *Prostaglandins Leukot. Essent. Fatty Acids* **2005**, *73*, 113–119.

46. Kohno, H.; Yasui, Y.; Suzuki, R.; Hosokawa, M.; Miyashita, K.; Tanaka, T. Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPAR γ expression and alteration of lipid composition. *Int. J. Cancer* **2004**, *110*, 896–901.
47. Kohno, H.; Suzuki, R.; Yasui, Y.; Hosokawa, M.; Miyashita, K.; Tanaka, T. Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. *Cancer Sci.* **2004**, *95*, 481–486.
48. Yasui, Y.; Kim, M.; Oyama, T.; Tanaka, T. Colorectal carcinogenesis and suppression of tumor development by inhibition of enzymes and molecular targets. *Curr. Enzym. Inhib.* **2009**, *5*, 1–26.
49. Yasui, Y.; Kim, M.; Tanaka, T. PPAR Ligands for Cancer Chemoprevention. *PPAR Res.* **2008**, *2008*, doi:10.1155/2008/548919.
50. Tanaka, T.; Kohno, H.; Yoshitani, S.; Takashima, S.; Okumura, A.; Murakami, A.; Hosokawa, M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. *Cancer Res.* **2001**, *61*, 2424–2428.
51. Tsuzuki, T.; Tokuyama, Y.; Igarashi, M.; Miyazawa, T. Tumor growth suppression by alpha-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via lipid peroxidation. *Carcinogenesis* **2004**, *25*, 1417–1425.
52. Tsuzuki, T.; Igarashi, M.; Miyazawa, T. Conjugated eicosapentaenoic acid (EPA) inhibits transplanted tumor growth via membrane lipid peroxidation in nude mice. *J. Nutr.* **2004**, *134*, 1162–1166.
53. Noguchi, R.; Yasui, Y.; Hosokawa, M.; Fukunaga, K.; Miyashita, K. Bioconversion of Conjugated Linolenic acid to Conjugated Linoleic Acid. In *Essential Fatty Acids and Eicosanoids*; Huang, Y.S., Lin, S.J., Huang, P.C., Eds.; AOCS Press: Champaign, IL, USA, 2003; pp. 353–359.
54. Ha, Y.L.; Grimm, N.K.; Pariza, M.W. Anticarcinogens from fried ground beef: Heat-altered derivatives of linoleic acid. *Carcinogenesis* **1987**, *8*, 1881–1887.
55. Ip, C.; Chin, S.F.; Scimeca, J.A.; Pariza, M.W. Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. *Cancer Res.* **1991**, *51*, 6118–6124.
56. Ip, C.; Singh, M.; Thompson, H.J.; Scimeca, J.A. Conjugated linoleic acid suppresses mammary carcinogenesis and proliferative activity of the mammary gland in the rat. *Cancer Res.* **1994**, *54*, 1212–1215.
57. Sarkar, F.H.; Adsule, S.; Li, Y.; Padhye, S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. *Mini Rev. Med. Chem.* **2007**, *7*, 599–608.
58. Suzuki, R.; Noguchi, R.; Ota, T.; Abe, M.; Miyashita, K.; Kawada, T. Cytotoxic effect of conjugated trienoic fatty acids on mouse tumor and human monocytic leukemia cells. *Lipids* **2001**, *36*, 477–482.
59. Igarashi, M.; Miyazawa, T. Preparation and fractionation of conjugated trienes from alpha-linolenic acid and their growth-inhibitory effects on human tumor cells and fibroblasts. *Lipids* **2005**, *40*, 109–113.
60. Beppu, F.; Hosokawa, M.; Tanaka, L.; Kohno, H.; Tanaka, T.; Miyashita, K. Potent inhibitory effect of trans9, trans11 isomer of conjugated linoleic acid on the growth of human colon cancer cells. *J. Nutr. Biochem.* **2006**, *17*, 830–836.

61. Gupta, R.A.; Dubois, R.N. Controversy: PPARgamma as a target for treatment of colorectal cancer. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2002**, *283*, G266–G269.
62. Sporn, M.B.; Suh, N.; Mangelsdorf, D.J. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). *Trends Mol. Med.* **2001**, *7*, 395–400.
63. McCarty, M.F. Activation of PPARgamma may mediate a portion of the anticancer activity of conjugated linoleic acid. *Med. Hypotheses* **2000**, *55*, 187–188.
64. Tontonoz, P.; Hu, E.; Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell* **1994**, *79*, 1147–1156.
65. DuBois, R.N.; Gupta, R.; Brockman, J.; Reddy, B.S.; Krakow, S.L.; Lazar, M.A. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. *Carcinogenesis* **1998**, *19*, 49–53.
66. Kitamura, S.; Miyazaki, Y.; Shinomura, Y.; Kondo, S.; Kanayama, S.; Matsuzawa, Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. *Jpn. J. Cancer Res.* **1999**, *90*, 75–80.
67. Elstner, E.; Muller, C.; Koshizuka, K.; Williamson, E.A.; Park, D.; Asou, H.; Shintaku, P.; Said, J.W.; Heber, D.; Koeffler, H.P. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells *in vitro* and in BNX mice. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 8806–8811.
68. Kubota, T.; Koshizuka, K.; Williamson, E.A.; Asou, H.; Said, J.W.; Holden, S.; Miyoshi, I.; Koeffler, H.P. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both *in vitro* and *in vivo*. *Cancer Res.* **1998**, *58*, 3344–3352.
69. Yoshida, K.; Hirose, Y.; Tanaka, T.; Yamada, Y.; Kuno, T.; Kohno, H.; Katayama, M.; Qiao, Z.; Sakata, K.; Sugie, S.; *et al.* Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. *Cancer Sci.* **2003**, *94*, 365–371.
70. Shimada, T.; Kojima, K.; Yoshiura, K.; Hiraishi, H.; Terano, A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. *Gut* **2002**, *50*, 658–664.
71. Yang, W.L.; Frucht, H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. *Carcinogenesis* **2001**, *22*, 1379–1383.
72. Clay, C.E.; Namen, A.M.; Atsumi, G.; Willingham, M.C.; High, K.P.; Kute, T.E.; Trimboli, A.J.; Fonteh, A.N.; Dawson, P.A.; Chilton, F.H. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. *Carcinogenesis* **1999**, *20*, 1905–1911.
73. Kohno, H.; Yoshitani, S.; Takashima, S.; Okumura, A.; Hosokawa, M.; Yamaguchi, N.; Tanaka, T. Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. *Jpn. J. Cancer Res.* **2001**, *92*, 396–403.
74. Tsubouchi, Y.; Sano, H.; Kawahito, Y.; Mukai, S.; Yamada, R.; Kohno, M.; Inoue, K.; Hla, T.; Kondo, M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. *Biochem. Biophys. Res. Commun.* **2000**, *270*, 400–405.